Portal de Periódicos da CAPES

Cocktail Strategy: Complications and Limitations

1993; Wiley; Volume: 33; Issue: 11 Linguagem: Inglês

10.1002/j.1552-4604.1993.tb01936.x

1552-4604

Moreno Paolini, G. Biagi, C. Bauer, Giorgio Cantelli‐Forti,

Pharmaceutical Economics and Policy

The Journal of Clinical PharmacologyVolume 33, Issue 11 p. 1011-1012 Free Access Cocktail Strategy: Complications and Limitations Dr. M. Paolini, Corresponding Author Dr. M. Paolini Dipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio, BolognaDipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio 48, 40126 Bologna, Italy.Search for more papers by this authorDr. G. L. Biagi, Dr. G. L. Biagi Dipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio, BolognaSearch for more papers by this authorDr. C. Bauer, Dr. C. Bauer Dipartimento di Fisiologica e Biochimica, Laboratori di Biochimica, Pisa, Italy.Search for more papers by this authorDr. G. Cantelli-Forti, Dr. G. Cantelli-Forti Dipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio, BolognaSearch for more papers by this author Dr. M. Paolini, Corresponding Author Dr. M. Paolini Dipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio, BolognaDipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio 48, 40126 Bologna, Italy.Search for more papers by this authorDr. G. L. Biagi, Dr. G. L. Biagi Dipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio, BolognaSearch for more papers by this authorDr. C. Bauer, Dr. C. Bauer Dipartimento di Fisiologica e Biochimica, Laboratori di Biochimica, Pisa, Italy.Search for more papers by this authorDr. G. Cantelli-Forti, Dr. G. Cantelli-Forti Dipartimento di Farmacologia, Laboratori di Tossicologia Biochimica, Via Irnerio, BolognaSearch for more papers by this author First published: November 1993 https://doi.org/10.1002/j.1552-4604.1993.tb01936.xCitations: 16AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Guttendorf RJ, Wedlund PJ: Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol 1992; 32: 107– 117. 2 Clark DWJ: Genetically determined variability in acetylation and oxidation, Therapeutic implications. Drugs 1985; 29: 342– 375. 3 Rolling MV: Polymorphic drug metabolism. Clin Pharm 1989; 852– 863. 4 Brosen K: Recent developments in hepatic drug oxidation. Implictions for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220– 239. 5 Schellens JHM, Soons PA, Van-der-Wart JH, Hovers JW, Breimer DD: Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. Clin Pharm 1991; 31: 175– 178. 6 Breimer DD, Schellens JHM: A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990; 11: 223– 225. 7 Okey AB: Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990; 45: 241– 298. 8 Bast A, Savenije-Chapel EM, Kroes BH: Inhibition of mono-oxygenase and oxidase activity of rat-hepatic cytochrome P-450 by H2-receptor blockers. Xenobiotica 1984; 14: 399– 408. 9 Gonder JC, Proctor RA, Will JA: Genetic differences in oxygen toxicity are correlated with cytochrome P-450 inducibility. Proc Natl Acad Sci 1985; 82: 6315– 6319. 10 Paolini M, Biagi GL, Bauer C, Cantelli-Forti G: On the nature of non-genotoxic carcinogens. A unified theory including NGCs, co-carcinogens and promoters. Mutat Res 1992; 281: 245– 246. 11 Paolini M, Bauer C, Biagi GL, Cantelli-Forti G: Do cytochromes P-448 and P-450 have different functions? Biochem Pharmacol 1989; 38: 2223– 2225. 12 Paolini M, Biagi GL, Bauer C, Cantelli-Forti G: Is clonal adaptation a product of evolution over the millennia? [comment]. Biochem Pharmacol 1991; 42: 457– 458. 13 Pozniak PC: The carcinogenicity of caffeine and coffee: a review. J Am Diet Assoc 1985; 85: 1127– 1133. 14 Shinozuka H, Lombardi B, Abanobi SE: A comparative study of the efficacy of four barbiturates as promoters of the development of gamma-glutamyltranspeptidase-positive foci in the liver of carcinogen treated rats. Carcinogenesis 1982; 8: 67– 71. 15 Nims RW, Devor DE, Henneman JR, Lubet RA: Induction of alkoxyresorufin O-dealkylases, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates. Carcinogenesis 1987; 8: 67– 71. 16 Riedel L, Obe B: Mutagenicity of antiepileptic drugs. II. Phenytoin, primidone and phenobarbital. Mutat Res 1984; 138: 71– 74. 17 Habedank M, Esser KJ, Brull D, Kotlarek F, Stumpf C: Increased sister chromatid exchanges in epileptic children during long-term therapy with phenytoin. Hum Genet 1982; 61: 71– 73. 18 Nelson SD, Mitchell JR, Jbing E, Sasame H: Cytochrome P-450-mediated oxidation of 2-hydroxyestrogens to reactive intermediates. Biochem Biophys Res Commun 1976; 70: 1157– 1162. 19 Oas Isk, Lau CC, Pordee AB: Mutat Res 1984; 131: 71– 79. 20 Koren G, Demitrakoudis D, Weksberg R, Rieder M, Smear NH, Sonely M, Mandling B, Spielberg PS: Neuroblastoma after prenatal exposure to phenytoin: cause and effect? Teratology 1989; 40: 157– 162. 21 Wong M, Wells PG: Effects of N-acetylcysteine on fetal development and on phenytoin teratogenicity in mice. Teratogenesis Carcinog Mutat 1988; 8: 65– 79. 22 Martz F, Failinger C, Blake DA: Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther 1977; 203: 231– 239. 23 Brown NA: Teratogenicity testing in vitro: status of validation studies. Arch Toxicol 1987; 11: 105– 114. 24 Camen RL: Clin Pharmacol Ther 1964; 5: 480– 514. 25 Thomann P, Hess R: Handb Exp Pharm 1980; 55: 549– 567. 26 IARC: Monograph on the Evaluation of the Carcinogenic Risk of Chemicals to Human 1977; 13: 201– 225 and 1982;4:215–217. 27 Vessel ES: Clin Pharmacol Ther 1979; 26: 275– 286. 28 Park BK, Breckenridge AM: Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981; 6: 1– 24. 29 Boobis AR, Davies DS: Human cytochromes P-450. Xenobiotica 1984; 14: 151– 185. 30 Renton KW: Factors affecting drug biotransformation. Clin Biochem 1986; 19: 72– 75. Citing Literature Volume33, Issue11November 1993Pages 1011-1012 ReferencesRelatedInformation